To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
Vancouver-based antibody developer AbCellera Biologics said it expects to raise up to C$500 million (US$391 million) in its initial public offering on Nasdaq, Reuters reported.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
Copyright PEI Media
Not for publication, email or dissemination